REGN Quantitative Stock Analysis

Regeneron Pharmaceuticals Inc (REGN) achieved a 71% rating using Validea's Benjamin Graham 'Value Investor' model, positioning it as the highest-rated stock by this methodology. While the large-cap biotech passed critical fundamental criteria such as sales, current ratio, debt, and long-term EPS growth, its P/E and Price/Book ratios failed the strict deep-value screens, indicating that its current valuation metrics do not align with the model's typical threshold for strategic interest (80%+).

Analysis

Regeneron Pharmaceuticals (REGN) has been identified as the highest-rated security by Validea's Benjamin Graham-based Value Investor model, yet its score of 71% falls short of the 80% threshold that typically indicates strategic interest. The analysis reveals a dichotomy: the company demonstrates robust fundamental health, passing criteria for sales, current ratio, low long-term debt relative to net current assets, and sustained long-term EPS growth. However, it fails the model's stringent valuation tests for both Price-to-Earnings (P/E) and Price-to-Book (P/B) ratios. This suggests that while REGN is a fundamentally sound large-cap growth company, its current market valuation does not align with the deep-value principles central to the Graham methodology, which prioritizes a significant margin of safety based on low multiples.

Key Decisions for Investors

• Value-oriented investors should note that despite strong fundamentals, the failure on P/E and P/B criteria means REGN does not currently meet the strict entry requirements of a classic Graham-style deep-value approach.
• Investors with a growth or GARP (Growth at a Reasonable Price) mandate may interpret the strong performance on fundamental metrics like EPS growth and balance sheet health as a positive signal, potentially justifying the richer valuation.
• It is prudent to monitor REGN's key valuation ratios, as a market pullback could create a more attractive entry point, bringing the stock's price closer to the model's undervalued territory.